Pfizer ends pact with Claris; no plans to source products from Indian firm
This article was originally published in Scrip
Not unexpectedly, it has now been firmly established that Pfizer will not source products, at least for now, from Claris Lifesciences of India and that their previous arrangement has ceased to exist.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.